Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.

  • Mark L. Heaney
  • Published 2014 in Clinical advances in hematology & oncology : H&O


Columbia University -Medical Center, New York, New York. The advent of tyrosine kinase inhibitors (TKIs) as primary treatment in chronic myeloid leukemia (CML) has greatly changed expectations of both physicians and patients. The use of imatinib has led not only to reliable cytogenetic responses, but also to deeper "molecular" responses that have brought… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics